News

KV Pharmaceutical has signed an agreement with Gedeon Richter, USA for licensing rights to some of KV’ technologies and products in Women’s Health. Under this agreement, Gedeon Richter

Non-GAAP adjusted earnings from continuing operation per ADS increased by about 80% year-over-year to about RMB15.8 for fiscal 2008. For the fourth quarter of fiscal 2008, Revenues from

Takeda has launched two new dose strengths of Blopress Plus in Germany. These are fixed-dose combinations of 32mg candesartan. The maximum doses authorized in Europe are with 25mg

Allergan has received FDA approval for OZURDEX (dexamethasone intravitreal implant) 0.7mg, as the first drug therapy for the treatment of macular edema, following branch retinal vein occlusion (BRVO)

Cytokinetics has initiated first-time-in-humans, phase-I clinical trial of CK-2017357 in healthy male volunteers. CK-2017357 is a fast skeletal muscle troponin activator, and is the lead drug candidate of

Highlights: Group operating profit before non-recurring costs GBP334,000 (2008: GBP1,033,000) Non-recurring costs of GBP1,117,000 primarily represent business relocation expenses and redundancy and employment contract severance costs Loss before

Canada-based Paladin Labs and Sylphar have entered into an agreement to develop and market an oral dissolving teeth whitening film strip in Europe. Under the agreement, Sylphar and

Seattle Genetics has initiated phase-II clinical trial of SGN-35 for patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). SGN-35 is an antibody-drug conjugate (ADC) that

Antares Pharma’ partner BioSante has said that the LibiGel Safety Study External Executive Committee has recommended continuation of the LibiGel phase-III clinical program. The decision of the committee